person · Reporting owner
Patel Samir Rashmikant
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akari Therapeutics PlcAKTX · Entity 7692 | Director · 10% owner | July 07, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akari Therapeutics Plc
Report date July 07, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary Shares representing Ordinary SharesSEC Table I · non-derivative | IndirectPranaBio Investments LLC | 76,976 |
Reported balance
After 2026-07-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-07 · Exercise / conversion · Acquired 1,209 · Balance 76,976 |
| American Depositary Shares representing Ordinary SharesSEC Table I · non-derivative | IndirectPranaBio Investments LLC | 92,442 |
Reported balance
After 2026-07-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-07 · Exercise / conversion · Acquired 15,466 · Balance 92,442 |
| American Depositary Shares representing Ordinary SharesSEC Table I · non-derivative | IndirectPranaBio Investments LLC | 98,241 |
Reported balance
After 2026-07-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-07-07 · Exercise / conversion · Acquired 5,799 · Balance 98,241 |
| Pre-Funded Warrant to purchase American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $8.00 | IndirectPranaBio Investments LLC | 0 |
Reported balance
After 2026-07-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-07 · Exercise / conversion · Acquired 1,209 · Balance 0 F1: Each American Depositary Share ("ADS") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. F2: The pre-funded warrants remain exercisable until fully exercised. |
| Pre-Funded Warrant to purchase ADSsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectPranaBio Investments LLC | 0 |
Reported balance
After 2026-07-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-07 · Exercise / conversion · Acquired 15,466 · Balance 0 F4: The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16. F3: The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026. F2: The pre-funded warrants remain exercisable until fully exercised. |
| Pre-Funded Warrant to purchase ADSsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectPranaBio Investments LLC | 0 |
Reported balance
After 2026-07-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-07 · Exercise / conversion · Acquired 5,799 · Balance 0 F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs. F3: The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026. F2: The pre-funded warrants remain exercisable until fully exercised. |
| American Depositary Shares representing Ordinary SharesSEC Table I · non-derivative | Direct | 3,566 |
Reported balance
Holding disclosure · report date 2026-07-07 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,566 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share.
F2: The pre-funded warrants remain exercisable until fully exercised.
F3: The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
F4: The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16.
F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytoDyn Inc.
Report date November 24, 2021 · Filed November 30, 2021 · Amendment
Section 16 reporting ended · disclosed 2021-11-30. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2031-10-18 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-11-24 · Disposition to issuer · Disposed 225,000 · Balance 0 F1: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. |
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2031-10-18 | Direct | 112,500 |
Reported balance
After 2021-11-24 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2021-11-24 · Grant · Acquired 112,500 · Balance 112,500 F1: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. |
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2030-06-25 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2021-11-24 · Disposition to issuer · Disposed 225,000 · Balance 0 F1: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F2: 56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021. |
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2030-06-25 | Direct | 225,000 |
Reported balance
After 2021-11-24 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2021-11-24 · Grant · Acquired 225,000 · Balance 225,000 F1: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F2: 56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021. |
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2030-04-17 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2021-11-24 · Disposition to issuer · Disposed 12,329 · Balance 0 F1: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. |
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2030-04-17 | Direct | 12,329 |
Reported balance
After 2021-11-24 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2021-11-24 · Grant · Acquired 12,329 · Balance 12,329 F1: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. |
Filing footnotes · ownership attribution and instrument terms
F1: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service.
F2: 56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 17, 2026 10:03 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | Exercise / conversionPre-Funded Warrant to purchase ADSs · Derivative | 5,799 | $16.16 Strike: $0.00 | $93,711.84 |
DisclosureSEC source: 0001493152-26-033634 · ownership.xml · derivative · entry 7 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 0 Underlying: American Depositary Shares representing Ordinary Shares · 5,799 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs. F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs. F3 · derivative.exercise_date: The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026. F2 · derivative.expiration_date: The pre-funded warrants remain exercisable until fully exercised. Read SEC document |
| July 07, 2026 Filed Jul 17, 2026 10:03 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | Exercise / conversionPre-Funded Warrant to purchase ADSs · Derivative | 15,466 | $16.16 Strike: $0.00 | $249,930.56 |
DisclosureSEC source: 0001493152-26-033634 · ownership.xml · derivative · entry 6 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 0 Underlying: American Depositary Shares representing Ordinary Shares · 15,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16. F3 · derivative.exercise_date: The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026. F2 · derivative.expiration_date: The pre-funded warrants remain exercisable until fully exercised. Read SEC document |
| July 07, 2026 Filed Jul 17, 2026 10:03 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | Exercise / conversionPre-Funded Warrant to purchase American Depositary Shares · Derivative | 1,209 | $32.00 Strike: $8.00 | $38,688.00 |
DisclosureSEC source: 0001493152-26-033634 · ownership.xml · derivative · entry 5 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 0 Underlying: American Depositary Shares representing Ordinary Shares · 1,209 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. F2 · derivative.expiration_date: The pre-funded warrants remain exercisable until fully exercised. Read SEC document |
| July 07, 2026 Filed Jul 17, 2026 10:03 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | Exercise / conversionAmerican Depositary Shares representing Ordinary Shares | 5,799 | $0.00 | $2.32 |
DisclosureSEC source: 0001493152-26-033634 · ownership.xml · nonDerivative · entry 3 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 98,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2026 Filed Jul 17, 2026 10:03 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | Exercise / conversionAmerican Depositary Shares representing Ordinary Shares | 15,466 | $0.00 | $6.19 |
DisclosureSEC source: 0001493152-26-033634 · ownership.xml · nonDerivative · entry 2 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 92,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2026 Filed Jul 17, 2026 10:03 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | Exercise / conversionAmerican Depositary Shares representing Ordinary Shares | 1,209 | $8.00 | $9,672.00 |
DisclosureSEC source: 0001493152-26-033634 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 76,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 231,997 | $0.40 Strike: $0.00 | $93,749.99 |
DisclosureSEC source: 0001493152-25-028418 · ownership.xml · derivative · entry 4 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 231,997 Underlying: American Depositary Shares representing Ordinary Shares · 231,997 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the "Note Exchange Unregistered Warrants"). F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase ADRs · Derivative | 231,997 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028418 · ownership.xml · derivative · entry 3 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 231,997 Underlying: American Depositary Shares representing Ordinary Shares · 231,997 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the "Note Exchange Unregistered Warrants"). F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 618,658 | $0.40 Strike: $0.00 | $249,999.70 |
DisclosureSEC source: 0001493152-25-028418 · ownership.xml · derivative · entry 2 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,658 Underlying: American Depositary Shares representing Ordinary Shares · 618,658 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase American Depositary Shares ("ADRs") · Derivative | 618,658 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028418 · ownership.xml · derivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,658 Underlying: American Depositary Shares representing Ordinary Shares · 618,658 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043938 · ownership.xml · derivative · entry 4 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: American Depositary Shares representing Ordinary Shares · 225,000 shares Expires 2035-03-20 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043938 · ownership.xml · derivative · entry 3 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: American Depositary Shares representing Ordinary Shares · 175,000 shares Expires 2035-03-20 F2 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantSeries B Warrants (Right to Buy) · Derivative | 406,250 | $1.12 Strike: $0.87 | $455,000.00 |
DisclosureSEC source: 0000950170-25-036486 · ownership.xml · derivative · entry 4 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 406,250 Underlying: American Depositary Shares representing Ordinary Shares · 406,250 shares Expires 2030-03-06 F2 · kind: On March 6, 2025, the Reporting Person acquired 406,250 ADS and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 406,250 ADS and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantSeries A Warrants (Right to Buy) · Derivative | 406,250 | $1.12 Strike: $0.87 | $455,000.00 |
DisclosureSEC source: 0000950170-25-036486 · ownership.xml · derivative · entry 3 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 406,250 Underlying: American Depositary Shares representing Ordinary Shares · 406,250 shares Expires 2026-03-06 F2 · kind: On March 6, 2025, the Reporting Person acquired 406,250 ADS and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 406,250 ADS and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 406,250 | $1.12 | $455,000.00 |
DisclosureSEC source: 0000950170-25-036486 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 3,031,005 F1 · security: Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On March 6, 2025, the Reporting Person acquired 406,250 ADS and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 406,250 ADS and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 152,672,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002864 · ownership.xml · derivative · entry 3 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,672,000 Underlying: Ordinary Shares, par value $0.0001 per share · 152,672,000 shares Expires 2035-01-03 F3 · derivative.exercise_price: The stock options have an exercise price of $0.000655 per Ordinary Share. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 208,000 | $0.00 | $124.80 |
DisclosureSEC source: 0000950170-25-002864 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 5,249,511,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On January 3, 2025, the Reporting Person acquired 208,000 Ordinary Shares at a purchase price of $0.0006 per Ordinary Share. F2 · price: On January 3, 2025, the Reporting Person acquired 208,000 Ordinary Shares at a purchase price of $0.0006 per Ordinary Share. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 400,000 | $0.00 | $200.00 |
DisclosureSEC source: 0000950170-24-141162 · ownership.xml · nonDerivative · entry 2 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 5,249,303,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F3 · kind: On December 27, 2024 the Reporting Person acquired 400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. F2 · price: On December 26, 2024, the Reporting Person acquired 3,200,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 3,200,000 | $0.00 | $1,600.00 |
DisclosureSEC source: 0000950170-24-141162 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 5,248,903,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On December 26, 2024, the Reporting Person acquired 3,200,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. F2 · price: On December 26, 2024, the Reporting Person acquired 3,200,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 7,500,000 | $0.00 | $3,750.00 |
DisclosureSEC source: 0000950170-24-140807 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 5,245,703,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On December 24, 2024, the Reporting Person acquired 7,500,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. F2 · price: On December 24, 2024, the Reporting Person acquired 7,500,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 1,400,000 | $0.00 | $700.00 |
DisclosureSEC source: 0000950170-24-140430 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 5,238,203,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On December 23, 2024, the Reporting Person acquired 1,400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. F2 · price: On December 23, 2024, the Reporting Person acquired 1,400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 1,400,000 | $0.00 | $700.00 |
DisclosureSEC source: 0000950170-24-140427 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 5,236,803,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On December 20, 2024, the Reporting Person acquired 1,400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. F2 · price: On December 20, 2024, the Reporting Person acquired 1,400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 22:50 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantWarrants (Right to Buy) · Derivative | 419,286,000 | $0.00 Strike: $0.00 | $503,143.20 |
DisclosureSEC source: 0000950170-24-132936 · ownership.xml · derivative · entry 4 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 419,286,000 Underlying: Ordinary Shares, par value $0.0001 per share · 419,286,000 shares Expires 2027-12-02 F4 · derivative.exercise_price: The warrants have an exercise price of $0.001130 per Ordinary Share. F2 · kind: On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant. F2 · price: On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 22:50 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 419,286,000 | $0.00 | $503,143.20 |
DisclosureSEC source: 0000950170-24-132936 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 5,235,403,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant. F2 · price: On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant. Read SEC document |
| November 30, 2024 Filed Dec 3, 2024 22:50 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 162,604,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-132936 · ownership.xml · derivative · entry 3 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,604,000 Underlying: Ordinary Shares, par value $0.0001 per share · 162,604,000 shares Expires 2034-11-30 F3 · derivative.exercise_price: The stock options have an exercise price of $0.000615 per Ordinary Share. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. Read SEC document |
| November 14, 2024 Filed Nov 19, 2024 01:02 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 1,404,622,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128190 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 4,816,117,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADSs"), each of which currently represents 2,000 Ordinary Shares. F2 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. ("Peak Bio"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Issuer ("Merger Sub"), pursuant to which Merger Sub merged with and into Peak Bio effective as of November 14, 2024, with Peak Bio surviving as a wholly owned subsidiary of the Issuer (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Peak Bio (each, a "Peak Share") was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") ADSs. F2 · shares: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. ("Peak Bio"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Issuer ("Merger Sub"), pursuant to which Merger Sub merged with and into Peak Bio effective as of November 14, 2024, with Peak Bio surviving as a wholly owned subsidiary of the Issuer (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Peak Bio (each, a "Peak Share") was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") ADSs. F3 · shares: Represents the number of Ordinary Shares acquired by the Reporting Person from the exchange of Peak Shares held by the Reporting Person at the Effective Time in accordance with the Exchange Ratio. F2 · price: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. ("Peak Bio"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Issuer ("Merger Sub"), pursuant to which Merger Sub merged with and into Peak Bio effective as of November 14, 2024, with Peak Bio surviving as a wholly owned subsidiary of the Issuer (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Peak Bio (each, a "Peak Share") was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") ADSs. Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 22:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 79,684,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-120185 · ownership.xml · derivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,684,000 Underlying: Ordinary Shares, par value $0.0001 per share · 79,684,000 shares Expires 2034-10-31 F1 · derivative.exercise_price: The stock options have an exercise price of $0.001255 per ordinary share, par value $0.0001 per share ("Ordinary Share"). F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 22:34 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 175,080,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111796 · ownership.xml · derivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,080,000 Underlying: Ordinary Shares, par value $0.0001 per share · 175,080,000 shares Expires 2034-09-30 F1 · derivative.exercise_price: The stock options have an exercise price of $0.001490 per ordinary share, par value $0.0001 per share ("Ordinary Share"). F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 91,396,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-080542 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,396,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · shares: These shares represent restricted stock units ("RSUs") granted under the Issuer's 2023 Equity Incentive Plan, with each such RSU representing the right to receive one ordinary share, par value $0.0001. One-hundered percent (100%) of the RSUs vested on the date of grant, or June 30, 2024. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:45 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantWarrants (Right to Buy) · Derivative | 1,326,258,000 | $0.00 Strike: $0.00 | $1,193,632.20 |
DisclosureSEC source: 0000950170-24-068771 · ownership.xml · derivative · entry 2 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 1,326,258,000 Underlying: Ordinary Shares, par value $0.0001 per share · 1,326,258,000 shares Expires 2027-05-31 F3 · derivative.exercise_price: The warrants have an exercise price of $0.000895 per Ordinary Share. F2 · kind: On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant. F2 · price: On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:45 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 1,326,258,000 | $0.00 | $1,193,632.20 |
DisclosureSEC source: 0000950170-24-068771 · ownership.xml · nonDerivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · PranaBio Investments LLC Disclosed balance after: 3,411,495,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant. F2 · price: On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 23:30 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 12,329 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0000899243-21-046250 · doc4.xml · derivative · entry 6 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,329 Underlying: Common Stock · 12,329 shares Expires 2030-04-17 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 23:30 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified Stock Option · Derivative | 12,329 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0000899243-21-046250 · doc4.xml · derivative · entry 5 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,329 shares Expires 2030-04-17 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 23:30 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 225,000 | Not disclosed Strike: $6.15 | Not disclosed |
DisclosureSEC source: 0000899243-21-046250 · doc4.xml · derivative · entry 4 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-06-25 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F2 · derivative.exercise_date: 56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 23:30 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified Stock Option · Derivative | 225,000 | Not disclosed Strike: $6.15 | Not disclosed |
DisclosureSEC source: 0000899243-21-046250 · doc4.xml · derivative · entry 3 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2030-06-25 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F2 · derivative.exercise_date: 56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 23:30 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 93,750 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0000899243-21-046250 · doc4.xml · derivative · entry 2 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2031-10-18 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · derivative.exercise_date: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 23:30 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified Stock Option · Derivative | 225,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0000899243-21-046250 · doc4.xml · derivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2031-10-18 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · derivative.exercise_date: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 23:31 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 12,329 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0000899243-21-046333 · doc4a.xml · derivative · entry 6 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,329 Underlying: Common Stock · 12,329 shares Expires 2030-04-17 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 23:31 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified Stock Option · Derivative | 12,329 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0000899243-21-046333 · doc4a.xml · derivative · entry 5 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,329 shares Expires 2030-04-17 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 23:31 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 225,000 | Not disclosed Strike: $6.15 | Not disclosed |
DisclosureSEC source: 0000899243-21-046333 · doc4a.xml · derivative · entry 4 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-06-25 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F2 · derivative.exercise_date: 56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 23:31 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified Stock Option · Derivative | 225,000 | Not disclosed Strike: $6.15 | Not disclosed |
DisclosureSEC source: 0000899243-21-046333 · doc4a.xml · derivative · entry 3 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2030-06-25 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F2 · derivative.exercise_date: 56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 23:31 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 112,500 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0000899243-21-046333 · doc4a.xml · derivative · entry 2 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-10-18 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · derivative.exercise_date: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 23:31 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified Stock Option · Derivative | 225,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0000899243-21-046333 · doc4a.xml · derivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2031-10-18 F1 · kind: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · price: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. F1 · derivative.exercise_date: The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 20:10 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 225,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000899243-21-040748 · doc4.xml · derivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2031-10-18 F1 · derivative.exercise_date: The options will vest in 12 equal monthly installments beginning on July 1, 2021, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:47 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 225,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001807094-20-000012 · primary_doc.xml · derivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-06-25 F1 · derivative.exercise_date: 56,250 shares vest on August 31, 2020; the balance vests in equal amounts on November 30, 2020, February 28, 2021 and May 31, 2021, subject to amendment to the equity incentive plan. Read SEC document |
| April 17, 2020 Filed Apr 22, 2020 21:37 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option · Derivative | 12,329 | $2.25 Strike: $2.25 | $27,740.25 |
DisclosureSEC source: 0001702447-20-000004 · primary_doc.xml · derivative · entry 1 Patel Samir Rashmikant · CIK 0001702447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,329 Underlying: Common Stock · 12,329 shares Expires 2030-04-17 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.